A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients Over Age 60 in First Remission

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

S Luger;V Wang;J Rowe;M Litzow;E Paietta;R Kettering;H Lazarus;W Rybka;M Craig;J Karp;B Cooper;A Makary;L Kaminer;F Appelbaum;R Larson;M Tallman Leukemia Research Dec;111:106736

PMid: PMID34773794 | PMC number: PMC8643322

Tipifarnib as maintenance therapy In acute myeloid leukemia (AML) improves survival in women with high risk disease. Results of the phase III intergroup trial E2902

S Luger;X Yao;E Paietta;R Ketterling;W Rybka;M Litzow;JM Rowe;R Larson;F Appelbaum;M Tallman Blood 126(23):1308; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;